Experienced in Restrictive Cardiomyopathy (RCM)

Jean-pierre P. Mulkay

CHU Saint Pierre
Brussels, BRU, BE 
Experienced in Restrictive Cardiomyopathy (RCM)
CHU Saint Pierre
Brussels, BRU, BE 
OverviewLocationsClinical Research

Overview

Jean-pierre Mulkay practices in Brussels, Belgium. Mr. Mulkay is rated as an Experienced expert by MediFind in the treatment of Restrictive Cardiomyopathy (RCM). His top areas of expertise are Hepatitis C, Hepatitis, Cirrhosis, and Constrictive Pericarditis.

His clinical research consists of co-authoring 21 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Restrictive Cardiomyopathy (RCM).

Gender
Male

Locations

CHU Saint Pierre
Brussels, BRU, Belgium
Other Locations
ZNA Antwerp
Antwerpen, VLG, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A first-time-in Human (FTIH), Phase I/II, Randomized, Multi-centric, Single-blind, Controlled Dose-escalation Study to Evaluate the Reactogenicity, Safety, Immunogenicity and Efficacy of GSK Biologicals' HBV Viral Vector Vaccines Given in a Prime-boost Schedule With Sequential or Co-administration of Adjuvanted Proteins Therapeutic Vaccine (GSK3528869A) in Chronic Hepatitis B Patients (18-65 Years Old) Well Controlled Under Nucleo(s)Tide Analogue (NA) Therapy
A first-time-in Human (FTIH), Phase I/II, Randomized, Multi-centric, Single-blind, Controlled Dose-escalation Study to Evaluate the Reactogenicity, Safety, Immunogenicity and Efficacy of GSK Biologicals' HBV Viral Vector Vaccines Given in a Prime-boost Schedule With Sequential or Co-administration of Adjuvanted Proteins Therapeutic Vaccine (GSK3528869A) in Chronic Hepatitis B Patients (18-65 Years Old) Well Controlled Under Nucleo(s)Tide Analogue (NA) Therapy
Enrollment Status: Terminated
Publish Date: November 29, 2024
Intervention Type: Biological, Drug
Study Drugs: ChAd155-hIi-HBV, HBc-HBs/AS01B-4, MVA-HBV
Study Phase: Phase 1/Phase 2

21 Total Publications

A regular screening for hepatitis delta virus among chronic hepatitis B carriers improves the diagnostic of this infection and of subsequent cirrhosis development.
A regular screening for hepatitis delta virus among chronic hepatitis B carriers improves the diagnostic of this infection and of subsequent cirrhosis development.
Journal: United European gastroenterology journal
Published: August 02, 2023

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Mulkay's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile